Abstract
Cardio vascular disease (CVD) is the end result of the accumulation of atheromatous plaques within the walls of the coronary arteries and remains the leading cause of death worldwide. Vascular inflammation and associated ongoing inflammatory responses have been considered as the critical culprits in the pathogenesis of CVD. Moreover, the activation of inflammatory pathways is not confined to coronary lesions only but involves the activation of neutrophils, monocytes and lymphocytes in peripheral blood. In view of high mortality rate associated with this devastated disease, it is essential that CVD and related complications should be taken care off at its earliest. To achieve that goal, some inflammatory mediators could be potentially targeted. In the current article, we will highlight targeting some inflammatory mediators viz. IL-1, IL-6, TNF-α etc for CVD management. As far as our knowledge goes, we are for the first time reporting the targeting inflammatory mediators especially IL-1, IL-6 and TNF-α together in a single article. Based on our review, we believe that scientific community will come up with certain anti-inflammatory agents against atherosclerosis in near future and hopefully that will be used for the successful management of CVD patients.
Keywords: Cardiovascular disease, Inflammation, IL-1, IL-6, TNF-α.
Current Pharmaceutical Design
Title:Cardiovascular disease management through restrained inflammatory responses
Volume: 22 Issue: 7
Author(s): Nasimudeen R. Jabir and Shams Tabrez
Affiliation:
Keywords: Cardiovascular disease, Inflammation, IL-1, IL-6, TNF-α.
Abstract: Cardio vascular disease (CVD) is the end result of the accumulation of atheromatous plaques within the walls of the coronary arteries and remains the leading cause of death worldwide. Vascular inflammation and associated ongoing inflammatory responses have been considered as the critical culprits in the pathogenesis of CVD. Moreover, the activation of inflammatory pathways is not confined to coronary lesions only but involves the activation of neutrophils, monocytes and lymphocytes in peripheral blood. In view of high mortality rate associated with this devastated disease, it is essential that CVD and related complications should be taken care off at its earliest. To achieve that goal, some inflammatory mediators could be potentially targeted. In the current article, we will highlight targeting some inflammatory mediators viz. IL-1, IL-6, TNF-α etc for CVD management. As far as our knowledge goes, we are for the first time reporting the targeting inflammatory mediators especially IL-1, IL-6 and TNF-α together in a single article. Based on our review, we believe that scientific community will come up with certain anti-inflammatory agents against atherosclerosis in near future and hopefully that will be used for the successful management of CVD patients.
Export Options
About this article
Cite this article as:
Jabir R. Nasimudeen and Tabrez Shams, Cardiovascular disease management through restrained inflammatory responses, Current Pharmaceutical Design 2016; 22 (7) . https://dx.doi.org/10.2174/1381612822666151209153823
DOI https://dx.doi.org/10.2174/1381612822666151209153823 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Future Treatment Options in Idiopathic Pulmonary Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacological Therapies for Pediatric and Neonatal ALI/ARDS: An Evidence-Based Review
Current Drug Targets Positive Social Interactions in a Lifespan Perspective with a Focus on Opioidergic and Oxytocinergic Systems: Implications for Neuroprotection
Current Neuropharmacology Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry The Antiprogestogen Mifepristone: A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy Potential Cell Signalling Mechanisms Involved in Differential Placental Angiogenesis in Mild and Severe Pre-Eclampsia
Current Vascular Pharmacology Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry Surrogate Outcomes for Progression in the Initial Stages of Diabetic Retinopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Surgical or Interventional Revascularization in Diabetic Patients with Coronary Artery Disease?
Current Diabetes Reviews Prevalence of Obesity, Hypertension, Diabetes, and Metabolic Syndrome and Its Cardiovascular Complications
Current Hypertension Reviews Genetic Polymorphisms of Type-1 and Type-2 Inflammatory Cytokines in Ischaemic Stroke
Vascular Disease Prevention (Discontinued) Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science Microarray Profiling Analysis Uncovers Common Molecular Mechanisms of Rubella Virus, Human Cytomegalovirus, and Herpes Simplex Virus Type 2 Infections in ECV304 Cells
Current Molecular Medicine